RenovoRx advances TAMP into borderline resectable pancreatic cancer with first patient enrolled in PRISM-TAMP trial
RNXT•RenovoRx said the first patient has been enrolled in the investigator-initiated PRISM-TAMP trial, advancing TAMP into borderline resectable pancreatic cancer.
1. Trial enrollment
RenovoRx said the first patient has been enrolled in the investigator-initiated PRISM-TAMP trial, which advances TAMP into borderline resectable pancreatic cancer.
